|
Subscribe to The Burrill Report | Don't forget to join us on  Facebook or  Twitter
Symplmed Sees Value in Being Direct
Podcast: July 22, 2013
Symplmed, a spin out of the biotech Xoma, is trying to radically alter the business model for pharmaceutical companies. What makes the company compelling is not its products, but the way it’s selling them. Symplmed is using technology to change the way drugs are marketed and the way drugmakers interact with patients, providers, and payers. We spoke to Erik Emerson, president and CEO of Symplmed about the company’s approach, what’s wrong with the way drugs are sold today, and the opportunities for drugmakers to provide greater value than their medications alone. Read More Here
By The Numbers
|
Biggest movers for the week ending July 19, 2013
|
| TICKER |
COMPANY |
CLOSING PRICE 7/12/2013 |
CLOSING PRICE 7/19/2013
|
PRICE CHANGE |
PERCENT CHANGE |
|
| ADVANCERS |
| MEDS |
Medistem |
1.05 |
1.50 |
0.45 |
42.9% |
| TTHI |
Transition Therapeutics |
3.00 |
4.15 |
1.15 |
38.3% |
| BCRX |
BioCryst Pharmaceuticals |
1.81 |
2.46 |
0.65 |
35.9% |
| SNGX |
Soligenix |
1.12 |
1.43 |
0.31 |
27.7% |
| CLSN |
Celsion |
1.13 |
1.42 |
0.29 |
25.7% |
| DECLINERS |
| AFFX |
Affymetrix |
5.17 |
4.09 |
-1.08 |
-20.9% |
| KOOL |
ThermoGenesis |
1.52 |
1.23 |
-0.29 |
-19.1% |
| RGLS |
Regulus Therapeutics |
12.10 |
10.08 |
-2.02 |
-16.7% |
| OXBT |
Oxygen Biotherapeutics |
3.08 |
2.60 |
-0.48 |
-15.6% |
| PXSL.Y |
Pharmaxis |
2.50 |
2.13 |
-0.37 |
-14.8% |
| Includes life sciences stocks with closing price of $1 or more on July 12, 2013, |
Medistem Signs Stem Cell Patent Agreement with Cytori
With $18 billion in debt, this week Detroit filed for bankruptcy, making the the Motor City the largest city in the United States to file for Chapter 9. The city’s population has declined by nearly half in the past 60 years, effectively eliminated tax revenues. Other economic news, including moderate second quarter earnings growth for most companies that released data, were encouraging enough to keep markets calm. Stock indices were fairly flat with The Dow Jones Industrial Average up 0.5 percent, the S&P 500 up 0.7 percent, and the Nasdaq Composite down 0.4 percent. The Burrill Select index was up 0.6 percent.
Medistem was the week’s biggest advancer, up 42.9 percent, on news of a patent licensing agreement with the stem cell company Cytori Therapeutics that granted Cytori exclusive rights to Medistem’s patent for methods of immune modulation using autologous mononuclear T regulatory cells isolated from adipose tissue.
ThermoGenesis, a supplier of enabling technologies for processing and storage of stem cells and other biological tissues, was down almost 20 percent after announcing a merger agreement with TotipotentRx. The merger will create a fully integrated regenerative medicine company, from cell to patient. ThermoGenesis will issue approximately more than 12 millionshares of its common stock to TotiRx, a value of approximately $18.6 million, based on ThermoGenesis' closing stock price of $1.49 on July 15, 2013.
Biotech Sizzles in Public Markets
Investors flock not only to IPOs, but to follow-on offerings as well.
While there has been a lot of attention focused on the hot market for biotech IPOs, follow-on offerings by U.S. biotech companies are also sizzling—up more than 70 percent this year—as the sector continues to outperform the broader market. Read More Here
| BURRILL INDICES |
12/31/2012 |
7/12/2013 |
7/19/2013 |
Week Change |
Year Change |
| Burrill Select |
589.98 |
863.05 |
868.26 |
0.6% |
47.2% |
| Burrill Large Cap |
711.61 |
1060.15 |
1062.01 |
0.2% |
49.2% |
| Burrill Mid-Cap |
309.52 |
435.86 |
433.10 |
-0.6% |
39.9% |
| Burrill Small Cap |
105.48 |
151.20 |
151.76 |
0.4% |
43.9% |
| Burrill Diagnostics |
191.32 |
214.49 |
216.97 |
1.2% |
13.4% |
| Burrill Personalized Medicine |
118.52 |
151.05 |
148.46 |
-1.7% |
25.3% |
| Burrill Biogreentech |
163.09 |
184.81 |
186.15 |
0.7% |
14.1% |
| NASDAQ |
3019.51 |
3600.08 |
3587.61 |
-0.3% |
18.8% |
| DJIA |
13104.14 |
15464.30 |
15543.74 |
0.5% |
18.6% |
| S&P 500 |
1426.19 |
1680.19 |
1692.09 |
0.7% |
18.6% |
| Amex Biotech |
1547.03 |
2178.67 |
2167.62 |
-0.5% |
40.1% |
| Amex Pharmaceutical |
369.57 |
431.79 |
431.15 |
-0.1% |
16.7% |
| NASDAQ Biotechnology Index |
1430.81 |
2017.25 |
2036.63 |
1.0% |
42.3% |
Biohackers Find a New Home in Carlsbad
City hopes to fuel job growth by tapping into citizen scientists.
Kevin Lustig, one of the founders of Bio, Tech and Beyond, a just christened non-profit incubator in Carlsbad, California aimed at providing laboratory space for a new breed of citizen scientists, says its motto captures the essence of his group’s effort: “Probably crazy, possibly brilliant.” Read More Here
Ayasdi Raises $30.6 million for Big Data Platform
Funding will be used to speed the discovery of insights from complex information in seconds.
Startup Ayasdi has raised $30.6 million in a series B venture financing to refine and expand its big data platform to sectors beyond life sciences and the defense industries. Read More Here
Avastin As Good As Lucentis for Wet AMD at a Tenth of the Price
Researchers say UK’s National Health Service could save $129 million a year from switching.
The National Health Service could save $129 million a year by using Avastin instead of Lucentis as a treatment for wet age-related macular degeneration, a leading cause of blindness in older adults, according to researchers who found the two drugs equally effective at treating the eye disease. Read More Here
Gene Therapy Startup Audentes Therapeutics Raises $30M
Biotech is focused on treatments for rare and debilitating muscle diseases.
Audentes Therapeutics has raised $30 million in a series A financing round to develop gene therapies to treat rare muscle diseases. Read More Here
National Institute of Health Cancels Clinical Trials in India
The weekly round-up of failed trials, missed targets, and other business mishaps.
Numerous clinical trials in India have been cancelled due to an unstable regulatory environment leaving the $500 million industry functioning at one-fifth of its capacity. India’s health ministry recently amended its Drugs and Cosmetics Act with new provisions for regulation and ethical supervision of trials, compensation of trial subjects, and mandatory accreditation of all stakeholders including institutional review boards, research institutions, sponsors and contract research organizations. Read More Here
Ipsen Acquires Syntaxin, Strikes R&D Deal with Harvard
French pharma targets Botulinum toxin for therapeutic candidates.
French pharma Ipsen is making a strategic push into the field of engineered botulinum toxins as potential therapeutic candidates in two separate but complementary deals—the acquisition of partner Syntaxin and a research collaboration with Harvard Medical School. Read More Here
Researchers Gain Understanding of Obesity Gene
One mutation affects both food intake and feeling of satisfaction after eating.
Researchers have connected the dots between a genetic mutation associated with obesity and a hormone known to control appetite that may add to our knowledge of how we perceive food and how we might treat obesity through drugs that target the hormone ghrelin. Read More Here
National Cancer Institute Opens Database of Genetic Variation of Cancer
Catalog is largest of its kind and expected to help researchers understand drug response and resistance.
The National Cancer Institute is making available a database of the genetic variation of cancer—the largest of its kind—to help researchers understand how to better tailor drugs to treat specific forms of the disease. Read More Here
|
Print
.gif)
